Top

Published in:

Open Access 01-12-2016 | Research article

Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations

Authors: Francesca Maria Rizzo, Raffaele Palmirotta, Andrea Marzullo, Nicoletta Resta, Mauro Cives, Marco Tucci, Franco Silvestris

Published in: BMC Cancer | Issue 1/2016

Abstract

Background

Gastrointestinal stromal tumors (GISTs) are characterized by mutations of KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) or PDGFRA (platelet-derived growth factor receptor α) that may be efficiently targeted by tyrosine kinase inhibitors (TKI). Notwithstanding the early responsiveness to TKI, the majority of GISTs progress, imposing the need for alternative therapeutic strategies. DOG1 (discovered on GIST-1) shows a higher sensitivity as a diagnostic marker than KIT, however its prognostic role has been little investigated.

Methods

We evaluated DOG1 expression by immunohistochemistry (IHC) in 59 patients with GISTs, and correlated its levels with clinical and pathological features as well as mutational status. Kaplan-Meier analysis was also applied to assess correlations of the staining score with patient recurrence-free survival (RFS).

Results

DOG1 was expressed in 66 % of CD117⁺ GISTs and highly associated with tumor size and the rate of wild-type tumors. Kaplan-Meier survival analysis showed that a strong DOG1 expression demonstrated by IHC correlated with a worse 2-year RFS rate, suggesting its potential ability to predict GISTs with poor prognosis.

Conclusions

These findings suggest a prognostic role for DOG1, as well as its potential for inclusion in the criteria for risk stratification.

Available only for authorised users

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.CrossRefPubMed

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.CrossRefPubMed

Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–66.CrossRefPubMed

Jones RL. Practical aspects of risk assessment in gastrointestinal stromal tumors. J Gastrointest Cancer. 2014;45(3):262–7.PubMedCentralCrossRefPubMed

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–65.CrossRefPubMed

Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer. 2014;14:685.PubMedCentralCrossRefPubMed

Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769–76.CrossRefPubMed

Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, et al. Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer. 2013;16(4):596–601.CrossRefPubMed

Lasota J, Xi L, Coates T, Dennis R, Evbuomwan MO, Wang ZF, et al. No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases. Mod Pathol. 2013;26(11):1488–91.CrossRefPubMed

10.

Hechtman JF, Zehir A, Mitchell T, Borsu L, Singer S, Tap W, et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes Cancer. 2015;54(3):177–84.CrossRefPubMed

11.

Cole WC. ANO1-ther brick in the wall--role of Ca2 + −activated Cl- channels of interstitial cells of Cajal in cholinergic motor control of gastrointestinal smooth muscle. J Physiol. 2011;589(Pt 19):4641–2.PubMedCentralCrossRefPubMed

12.

Katoh M. FLJ10261 gene, located within the CCND1-EMS1 locus on human chromosome 11q13, encodes the eight-transmembrane protein homologous to C12orf3, C11orf25 and FLJ34272 gene products. Int J Oncol. 2003;22(6):1375–81.PubMed

13.

Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57(2):259–70.CrossRefPubMed

14.

Stanich JE, Gibbons SJ, Eisenman ST, Bardsley MR, Rock JR, Harfe BD, et al. Ano1 as a regulator of proliferation. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G1044–51.PubMedCentralCrossRefPubMed

15.

Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, et al. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res. 2012;72(13):3270–81.PubMedCentralCrossRefPubMed

16.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, et al. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3661–70.PubMedCentralCrossRefPubMed

17.

Wada T, Tanabe S, Ishido K, Higuchi K, Sasaki T, Katada C, et al. DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach. World J Gastroenterol. 2013;19(47):9133–6.PubMedCentralCrossRefPubMed

18.

Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009;33(3):437–46.CrossRefPubMed

19.

Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33(9):1401–8.CrossRefPubMed

20.

Sui XL, Wang H, Sun XW. Expression of DOG1, CD117 and PDGFRA in gastrointestinal stromal tumors and correlations with clinicopathology. Asian Pac J Cancer Prev. 2012;13(4):1389–93.CrossRefPubMed

21.

Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.CrossRefPubMed

22.

Sözütek D, Yanık S, Akkoca AN, Sözütek A, Ozdemir ZT, Avşar CU, et al. Diagnostic and prognostic roles of DOG1 and Ki-67, in GIST patients with localized or advanced/metastatic disease. Int J Clin Exp Med. 2014;7(7):1914–22.PubMedCentralPubMed

23.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85(3):200–6.CrossRefPubMed

24.

Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008;455(7217):1210–5.CrossRefPubMed

25.

Hartzell C, Putzier I, Arreola J. Calcium-activated chloride channels. Annu Rev Plant Physiol Plant Mol Biol. 2005;67:719–58.

26.

Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006;395(1):1–19.PubMedCentralCrossRefPubMed

27.

Hwang DG, Qian X, Hornick JL. DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks. Am J Clin Pathol. 2011;135(3):448–53.CrossRefPubMed

28.

Kang YN, Jung HR, Hwang I. Clinicopathological and immunohistochemical features of gastointestinal stromal tumors. Cancer Res Treat. 2010;42(3):135–43.PubMedCentralCrossRefPubMed

29.

Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol. 1995;103(1):41–7.PubMed

30.

Agaimy A, Märkl B, Arnholdt H, Hartmann A, Schneider-Stock R, Chetty R. Sporadic segmental interstitial cell of Cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes. Int J Clin Exp Pathol. 2010;3(5):549–56.PubMedCentralPubMed

31.

Maki RG. The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). Clin Sarcoma Res. 2012;2(1):21.PubMedCentralCrossRefPubMed

32.

Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205–20.CrossRefPubMed

33.

Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or nomalignant potential. Lab Invest. 2004;84(7):874–83.CrossRefPubMed

34.

Zong L, Chen P. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis. World J Surg Oncol. 2014;12:71.PubMedCentralCrossRefPubMed

35.

Ríos-Moreno MJ, Jaramillo S, Pereira Gallardo S, Vallejo A, Mora M, García-Escudero A, et al. Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers? Pathol Res Pract. 2012;208(2):74–81.CrossRefPubMed

36.

Abdel-Hadi M, Bessa SS, Hamam SM. Evaluation of the novel monoclonal antibody against DOG1 as a diagnostic marker for gastrointestinal stromal tumors. J Egypt Natl Canc Inst. 2009;21(3):237–47.PubMed

37.

Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):e17.PubMedCentralCrossRefPubMed

Title: Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations
Authors: Francesca Maria Rizzo
Raffaele Palmirotta
Andrea Marzullo
Nicoletta Resta
Mauro Cives
Marco Tucci
Franco Silvestris
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-016-2111-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma

Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer

PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer

DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Molecular features of the cytotoxicity of an NHE inhibitor: Evidence of mitochondrial alterations, ROS overproduction and DNA damage

Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer